NasdaqGS - Nasdaq Real Time Price USD

Amgen Inc. (AMGN)

312.47

-2.25

(-0.71%)

At close: May 17 at 4:00 PM EDT

314.98

+2.51

(+0.80%)

After hours: May 17 at 7:28 PM EDT

Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC

Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.

Zacks yesterday

AMGN
-0.71%
LGNZZ

ANIP
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly

Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.

Zacks yesterday

VKTX

NVO

ROG.SW
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk

Could Amgen be the next stock to soar due to a GLP-1 drug?

Motley Fool yesterday

AMGN
-0.71%
LLY
-0.15%
NVO
FDA approves Amgen drug for tough-to-treat form of lung cancer

Imdelltra, a bispecific antibody targeting a protein called DLL3, is cleared for use following chemotherapy in treating extensive-stage small cell lung cancer.

BioPharma Dive yesterday

AMGN
-0.71%
Amgen’s IMDELLTRA receives FDA approval for lung cancer treatment

The accelerated approval was granted following promising results from the Phase II DeLLphi-301 clinical trial.

Pharmaceutical Technology yesterday

AMGN
-0.71%
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA has received accelerated approval based on the encouraging response rate and duration of response (DoR) observed in clinical studies. Continued approval for this indication may be contingent upon verificatio

PR Newswire yesterday

AMGN
-0.71%
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Zacks 2 days ago

AMGN
-0.71%
KRAS inhibitors: The next frontier beckons

There has been several developments in the KRAS inhibitor space, shaping the KRAS inhibitors of the future.

Pharmaceutical Technology 2 days ago

AMGN
-0.71%
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024

Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday, May 20, 2024 following the presentation of new data from TEZSPIRE® in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) International Conference on May 19 and 20, 2024. The presentation will also include an overview of additional programs from Amgen's innovative inflammation portfolio. Jay Bradner, executive vice president of Research and Development and chief

PR Newswire 2 days ago

AMGN
-0.71%
Amgen Inc's Dividend Analysis

Amgen Inc (NASDAQ:AMGN) has recently announced a dividend of $2.25 per share, set to be payable on June 7, 2024, with the ex-dividend date on May 16, 2024. As investors anticipate this upcoming payment, it's crucial to delve into the company's dividend history, yield, and growth rates. Utilizing data from GuruFocus, this analysis will explore Amgen Inc's dividend performance and evaluate its sustainability.

GuruFocus.com 3 days ago

AMGN
-0.71%
The Zacks Analyst Blog Highlights Amgen, Amazon.com, Apple, Boeing and Goldman Sachs

Amgen, Amazon.com, Apple, Boeing and Goldman Sachs are included in this Analyst Blog.

Zacks 5 days ago

AAPL

BA

AMGN
-0.71%
Amgen Is Working On a Wegovy Competitor -- What It Means for Investors

The biotech's pipeline extends far beyond this exciting weight-loss product.

Motley Fool 6 days ago

AMGN
-0.71%
We Wouldn't Be Too Quick To Buy Amgen Inc. (NASDAQ:AMGN) Before It Goes Ex-Dividend

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Simply Wall St. 7 days ago

AMGN
-0.71%
5 Stocks Driving Dow's Market-Beating Performance

Dow Jones outperforms at the start of May as the market rally broadens and reconstruction of the index finally pays off.

Zacks 8 days ago

AAPL

AMZN

BA
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. PT on Tuesday, May 14, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the genera

PR Newswire 9 days ago

AMGN
-0.71%
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025

Investors are well aware of the explosive growth potential in weight loss drug stocks. That growth began last year with Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). GLP-1 receptor agonist drugs commercialized by those firms have started a revolution in weight loss. The early stages of that revolution caused the share prices of those already well established firms to double. Forecasts suggest that there is plenty of growth remaining in each. Thus, there is plenty of logic behind the decision

InvestorPlace 9 days ago

LLY
-0.15%
PFE
-0.97%
NVO
Q1 2024 CytomX Therapeutics Inc Earnings Call

Q1 2024 CytomX Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 9 days ago

CTMX

AMGN
-0.71%
Sector Superstars: 3 Stocks Generating the Most Buzz on Wall Street

During this earnings season, Wall Street investors have been paying attention to stocks generating buzz in different sectors. Diversifying investments across the 11 sectors within the S&P 500 index could help weather short-term market volatility. Over the past 12 months, the best performing sector has been information technology, returning well over 30%. Consumer discretionary sector with nearly 20% follows it, and the health care sector holds over 6%. By comparison, the S&P 500 index, which rep

InvestorPlace 9 days ago

FSLR

GM

AMGN
-0.71%
3 Tried and True Dividend Stocks to Buy for Your Portfolio

Picking income stocks can be challenging. Some companies pay dividends only to cut them in the future, and others are more focused on stock buybacks instead of dividends. However, research has shown that dividends provide investors with about 35% of their total returns over time. It varies year to year, but holding solid income stocks that consistently raise their annual payout has proven successful. The three dividend stocks to buy below have prioritized returning cash to shareholders and all h

InvestorPlace 11 days ago

AMGN
-0.71%
CVX

PEP
15 Best S&P 500 Dividend Stocks To Buy Now

In this article, we discuss 15 best S&P 500 dividend stocks to buy now. You can skip our detailed analysis of dividend stocks in the S&P 500 and their past performance, and go directly to read 5 Best S&P 500 Dividend Stocks To Buy Now. It’s been a dynamic first quarter for the stock market. […]

Insider Monkey 11 days ago

^GSPC

PG

HD

Performance Overview

Return	AMGN	S&P 500
YTD	+10.11%	+11.18%
1-Year	+42.74%	+29.04%
3-Year	+36.84%	+27.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Amgen Inc. (AMGN)

Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC

4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly

Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk

FDA approves Amgen drug for tough-to-treat form of lung cancer

Amgen’s IMDELLTRA receives FDA approval for lung cancer treatment

FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

KRAS inhibitors: The next frontier beckons

AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024

Amgen Inc's Dividend Analysis

The Zacks Analyst Blog Highlights Amgen, Amazon.com, Apple, Boeing and Goldman Sachs

Amgen Is Working On a Wegovy Competitor -- What It Means for Investors

We Wouldn't Be Too Quick To Buy Amgen Inc. (NASDAQ:AMGN) Before It Goes Ex-Dividend

5 Stocks Driving Dow's Market-Beating Performance

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025

Q1 2024 CytomX Therapeutics Inc Earnings Call

Sector Superstars: 3 Stocks Generating the Most Buzz on Wall Street

3 Tried and True Dividend Stocks to Buy for Your Portfolio

15 Best S&P 500 Dividend Stocks To Buy Now

Performance Overview